RA0278

antibody from Oursmab

Targeting: GPNMB HGFIN, NMB

Western blot (Supportive data in Antibodypedia)

ELISA (Supportive data in Antibodypedia)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0278

Provider

Oursmab

Product name

Glembatumumab (Biosimilar Reference Antibody) (GPNMB)

Antibody type

Monoclonal

Description

Glembatumumab vedotin (development code CDX-011) is an investigational antibody-drug conjugate (ADC) developed for the treatment of advanced breast cancer and melanoma. It is engineered by linking a fully human monoclonal antibody to a potent cytotoxic payload, monomethyl auristatin E (MMAE), via a cleavable linker. Glembatumumab vedotin functions as a targeted chemotherapy agent. The antibody component specifically binds to its target antigen, glycoprotein NMB (GPNMB), which is overexpressed on certain cancer cells. Upon binding, the ADC is internalized into the target cell, where the linker is cleaved, releasing the MMAE payload. MMAE disrupts microtubule networks, inhibits cell division, and induces apoptosis, leading to tumor cell death.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Glembatumumab (Biosimilar Reference Antibody) (GPNMB)-RA0278-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.

ELISA

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

ELISA plate pre-coated Antigen protein, can bind Glembatumumab (Biosimilar Reference Antibody) (GPNMB)-RA0278 in a linear range of 0.18¨C15 ng/mL.